The P73 gene is transcribed from two promoters, P1 and P2, that direct the expression of multiple transactivation competent (TA) and dominant negative (DN) isoforms. TAp73 transcription factors mediate cell cycle arrest and/ or apoptosis in response to DNA damage and are involved in developmental processes. P73 mRNA levels increase and the P1p73 promoter is upregulated during myogenic differentiation of C2C12 skeletal muscle satellite cells. The DNp73 proteins act as trans-repressors of p53-and p73-dependent transcription, and possess both antiapoptotic and pro-proliferative potential. Here, we show that DNp73a is expressed in proliferating C2C12 myoblasts, rapidly accumulates in differentiating myocytes and remains elevated in C2C12 myotubes. By combining transactivation assays and chromatin immunoprecipitation analysis, we could show that the upregulation of the P2p73 promoter during myogenic differentiation is mediated by the coordinated recruitment and activity of MyoD and p53/p73. Abrogation of DNp73 expression by specific siRNA led to a strong potentiation of the spontaneous apoptosis of C2C12 myoblasts induced to differentiate. Finally, unlike TAp73 that contributes to DNA damage-induced apoptosis of myotubes, endogenous DNp73 mediates the relative resistance of differentiated myotubes to DNA damage. Altogether, our findings identify DNp73a as an important target in designing strategies aimed at the potentiation of the regenerative potential of skeletal satellite cells.
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Keywords: p73; DNp73; myogenic differentiation; apoptosis The p53 paralog P73 gene encodes several variants of the p73 protein. At the 5 0 end of the gene, two alternative promoters drive the expression of N-terminal variants of p73, encoding transactivation competent (TA) and dominant negative (DN) isoforms (see for review, Levrero et al. 2000; Melino et al., 2002) . TAp73 transcription factors mediate cell cycle arrest and/or apoptosis in response to DNA damage and are involved in developmental processes. The DNp73 proteins expressed from a second intragenic promoter, the P2p73 promoter, act as trans-repressors of p53 and p73-dependent transcription and possess both antiapoptotic and pro-proliferative potential (Kartasheva et al. (2002) ; Vossio et al. (2002) ); in addition, at the 3 0 -end alternative splicing gives rise to seven different isoforms (denominated a, b, g, d, e, z, and Z.) with disparate C-terminal that execute partially overlapping, as well as distinct functions. The p73 proteins bind to the p53-responsive elements (p53REs) present in the regulatory regions of their transcriptional targets. The activation of defined subsets of target genes shared with p53 ensures the induction of growth arrest and apoptosis in response to DNA-damage and in other physiopathological responses . Transcriptional targets specific to p73 have been also identified, including genes involved in cell cycle regulation and differentiation (Fontemaggi et al., 2002) . The role of P73 gene products in development is supported by several observations including the phenotype of p73-deficient mutant mice . TAp73a is required in the development of telencephalon, olfactory system and pharyngeal arches in the zebrafish (Rentzsch et al., 2003) . Ectopic expression of TAp73a, but not p53, is sufficient to induce neurite outgrowth and neuronal differentiation markers in undifferentiated neuronal cells (De Laurenzi et al., 2000a) . TAp73a also facilitate differentiaton of oligodendrocytes in response to several specific stimuli (Billon et al., 2004) . Conversely, DNp73 has an important anti-apoptotic role in CNS cell (Pozniak et al., 2000 (Pozniak et al., , 2002 . Finally, p73 mRNAs increase during hematopoietic (Tschan et al., 2000) , keratynocyte (De Laurenzi et al., 2000b) and myogenic differentiation (Fontemaggi et al., 2001) .
The differentiation of skeletal myoblasts is characterized by permanent withdrawal from the cell cycle, biochemical and morphological maturation into mononucleated myocytes, and fusion into multinucleated myotubes. This program depends on the expression and activation of myogenic basic helix-loop-helix (bHLH) regulatory factors belonging to the MyoD family and on their cooperation with the myocytespecific enhancer binding factors MEF2 (Molkentin and Olson, 1996) . Both the cyclin-dependent kinase inhibitor p21 Waf1/Cip1 and the cell-cycle regulator pRb play a crucial role in myogenic differentiation. pRb is a transcriptional target of p53 in vivo in differentiated myotubes (Porrello et al., 2000) , thus providing a mechanicistic explanation for the observed increase in p53 expression levels during myogenic differentiation (Halevy, 1993) . Although the P1p73 promoter is upregulated during myogenic differentiation (Fontemaggi et al., 2001) , the role and function of the different p73 isoforms in this process is far less established, and it has been recently reported that ectopic expression of TAp73a in myoblasts rather prevents their commitment towards myogenic differentiation (Li et al., 2005) . In this study, we further characterize the relative role of p73 proteins and p53 in myogenic differentiation, and we uncovered a specific function of DNp73 in the protection of differentiated myotubes from DNA damage-induced apoptosis and in the inhibition of the spontaneous apoptosis of satellite skeletal muscle cells that fail to complete their differentiation.
DNp73 expression is up regulated during myogenic differentiation
P73 mRNA levels increase and the P1p73 promoter is upregulated during myogenic differentiation of C2C12 skeletal muscle satellite cells (Fontemaggi et al., 2001 ). The expression of the different p73 isoforms was analysed in proliferating myoblasts, during myogenic differentiation and in differentiated myotubes. As shown in Figure 1a , DNp73a is expressed in proliferating C2C12 myoblasts (GM); its protein levels increase already at 6 h of DM (lane 3), peak at 12 h (lane 4) and remain elevated in C2C12 myotubes (lanes 5-7) ( Figure 1a , left and right panels). TAp73a protein levels also rapidly increase in cells induced to differentiate, remain elevated up to 24 h and decline thereafter ( Figure 1a, lanes 3-7) . Interestingly, TAp73b protein levels become barely detectable at 6 h after shifting the cell cultures into DM ( Figure 1a, lanes 2 and 3) . This dramatic drop in TAp73b levels does not simply reflect the confluence status of myogenic satellite cells, but it is rather a general cell response to serum deprivation. Indeed, TAp73b levels do not change in proliferating myoblasts ( 
P2p73 promoter regulation in differentiating myocytes
The P2p73 promoter is upregulated in C2C12 myoblasts induced to differentiate, as shown by the increased activity of a transfected P2p73-luc reporter (Figure 2a ).
To define the mechanisms underlying the upregulation of the P2p73 promoter during myogenic differentiation, we first analysed the 2000 kb region upstream the DNp73 start codon in the exon 3 0 of the mouse P73 gene. We identified 5 p53-REs (Figure 2b ). The mouse P2p73 p53 D element corresponds to the human p53-RE 4 that is p53 and p73 responsive in vivo (Kartasheva et al., 2002; Vossio et al., 2002) . As both p53 and TAp73 are upregulated during myogenic differentiation (Puri et al., 2002; and Figure 1c ), we probed their contribution to the transcriptional regulation of the P2p73 promoter in differentiating C2C12 cells, using the selective DN mutants p53DD and p73DD. As shown in Figure 2c , p73DD abrogates the P2p73 activation whereas p53DD is active at 24 h but loses its activity at later times. We also identified, at least, five conserved CACCTG E-boxlike sequences (Figure 2b ) potentially targeted by the zinc finger homeodomain repressor ZEB in myoblasts and upregulated by MyoD during myogenic differentiation (Fontemaggi et al., 2001) . We found that ZEB overexpression has only a minor effect on the P2p73-luc reporter in C2C12 myoblasts (Figure 2d , GM) but inhibits the P2p73 promoter activity in differentiated C2C12 cells (Figure 2d ) and counteracts, in a dosedependent manner, the activation of the P2p73 promoter by MyoD (which competes with ZEB for binding to the same Ebox-like sequences to activate transcription) in 10T1/2 fibroblasts (Figure 2e ). These observations are confirmed and explained by the results of ChIP experiments on the endogenous P2p73 promoter (Figure 2f ). Acetylation of H4 histones bound to the endogenous P2p73 promoter parallels the kinetics of DNp73 transcripts ( Figure 1c ) and P2p73 promoter activity ( Figure 2a ) with a peak of H4-acetylation at 24 h and a return to the basal level at 72 h in DM (Figure 2f ). MyoD is recruited onto the P2p73 promoter at 24 h of DM and declines to the basal levels between 48 and 72 h. Although both p53 and p73 are bound to the P2p73 promoter in vivo in proliferating myoblasts, the binding of p73 remains unchanged whereas the occupancy by p53 increases slightly in the first 12-24 h (Figure 2f and data not shown) to decline sharply between 24 and 48 h. This latter observation is consistent with the observed low impact of p53DD overexpression on the activity of the P2p73 promoter in myotubes (DM48 and DM72) and might be explained by the redistribution of p53 onto other target genes. Indeed, p53 has been reported to be actively recruited onto the pRb promoter in differentiated myotubes (Porrello et al., 2000) , a property that is not shared by p73 (LB, unpublished observations). Altogether, these results indicate that the upregulation of the P2p73 promoter during myogenic differentiation is mediated by the coordinated recruitment and activity of MyoD and p53/p73. A recent report indicates that exogenously expressed p73a attenuates MyoD-dependent transcription and suppresses myogenic differentiation (Li et al., 2005) . To investigate the role of DNp73 vs TAp73 (and p53) proteins in myogenic differentiation, we applied two complementary approaches. First, p53, p73a, p73b or DNp73a were transiently expressed in C2C12 myoblasts along with the muscle-specific reporter MLC-bgal-nls. At 24 h after transfection, cells were shifted into DM to activate MyoD-dependent transcription from the MLC promoter. After 48 h in DM, nuclear bgal staining was examined by immunohistochemistry. As shown in Figure 3a , TAp73a, and to a lesser extent TAp73b and DNp73a, inhibit muscle-specific transcription whereas exogenously expressed p53 has rather a positive effect on the myogenic program (Figure 3a) . To corroborate these results, obtained from transient transfection experiments, we made use of specific siRNAs designed to target selectively p53, p73, TAp73, and DNp73 expression in C2C12 myoblasts induced to differentiate. Transfection of p53 siRNAs has a potent inhibitory In the middle and right panels, additional extracts were prepared from C3H10T1/2 fibroblasts and C2C7 myoblasts cultured in standard medium plus 10% FBS, shifted at low density in 0.1 FBS for 24 h (starved) and restimulated with serum ( þ FBS).
Immunoblots were analysed using a TAp73b-specific monoclonal antiboby (Upstate #GC15). (c) DNp73 transcripts are upregulated in differentiating C2C12 cells of the total RNA 1 mg was extracted from proliferating and differentiating C2C12 cells with the TRIzol reagent (GIBCO BRL) and RNA was reverse-transcribed and amplified by the Superscript One
Step RT-PCR (Invitrogen) using oligonucleotide primers that specifically recognize either TA or DNp73 transcripts (PCR condition and oligonucleotides are available upon request). Amplification of GAPDH transcripts was used to normalize equal loading of each RNA sample. Right panel: densitometric analysis performed as in (a). pCDNAHA-p73DD expresses a p73 miniprotein that acts as a selective DN of p73-dependent, but not p53-dependent, transcription (Irwin et al., 2000) . The p53DD plasmid is a gift from Dr M Oren. (e) ZEB inhibits the upregulation of the P2p73 promoter in differentiating myocytes. C2C12 cells were transiently transfected with the P2p73-luc reporter either alone or in combination with the ZEB expression vector (kindly provided by D Dean). Luciferase activity was determined in proliferating (GM) or differentiating (DM) myocytes at the indicated times. Error bars represent standard deviations from three independent experiments. (f) ZEB represses the MyoD-dependent activation of the P2p73 promoter. 10T/2 cells were transiently transfected with the P2p73-luc reporter either alone or in combination with the indicated expression vectors (pGal4-MyoD is a gift of Dr PL Puri). (g) In vivo occupancy of the DNp73 promoter. ChiP experiments were previously described . Cross-linked chromatin from proliferating and differentiating (12, 24, and 48 h) C2C12 cells was immunoprecipited with the indicated antibodies (anti-p53 polyclonal Ab-7 from Oncogene Sci; anti-MyoD (M-318) and anti-p73 (C-20 and H-79) polyclonal antibodies from Santa Cruz Biotechnology; antiacetyl-H4 from Upstate Biotech.) and analysed by PCR with specific DNp73 promoter primers (up: 5 0 -CTGAC TGCTCATGCTTTAGAGTGT-3 0 ; down:
DNp73 in myogenic differentiation
expression also led to a potentiation of myogenic differentiation (Figure 3b ). DNp73 proteins, which do not contain the N-terminal activation domain, have been shown to be transcriptionally inactive. This concept has been recently challenged since DNp73b, but not DNp73a, has been shown to activate transcription of some p53/p73 target genes and to promote cellgrowth arrest and apoptosis (Liu et al., 2004) . However, DNp73b is not expressed at detectable levels in C2C12 myoblasts and it is not induced during myogenic differentiation ( Figure 1a and LB unpublished observation). Thus, the biological effects of DNp73 abrogation in vivo is likely due to the loss of DNp73a expression and activity.
DNp73 protects differentiating myoblasts from apoptosis
Exit from cell cycle is an early step and a prerequisite in myogenic differentiation. Therefore, the most likely explanation for the positive effect of DNp73a loss might be by its interference with a timely exit from the cell cycle in myoblasts that become committed to differentiate. Myoblasts that fail to accomplish the differentiation program undergo spontaneous apoptosis (Wang and Walsh, 1996) . DNp73 expression raises early during differentiation ( Figure 1a) and has a potent antiapoptotic activity towards all the transactivation competent members of the p53 family. Abrogation of DNp73 expression leads to a strong potentiation of the spontaneous apoptosis of C2C12 myoblasts induced to differentiate (Figure 4a and b) . Loss of p53 expression has no effect on myoblasts apoptosis whereas the inihibition of TAp73 expression lowers the rate of C2C12 cell death (Figure 4a and b) . These results confirm in vivo the previous reports indicating that p53 is not involved in the spontaneous apoptosis of skeletal satellite cells undergoing differentiation and implicate TAp73 in the process. More importantly, these results show that endogenous DNp73 expression contributes substantially in protecting differentiating myocytes from apoptosis.
DNp73 contributes to differentiated myotubes resistance to apoptosis
Terminally differentiated myotubes are permanently withdrawn from the cell cycle and are partly resistant to DNA damage-induced apoptosis (Latella et al., 2004 ). Yet, myotubes, like myoblasts, activate several DNA damage sensors, signal transducers and effectors, including ATM, MRE11, Nbs1, and chk2 whereas p53 activation through Ser15(h)/18(m) phosphorylation is restricted to certain stimuli and only partially correlates with susceptibility to apoptosis (Latella et al., 2004) , thus suggesting a possible role for TAp73. The crosslinking agent cisplatin activates p53-and p73-dependent apoptosis in several cell types including C2C12 myoblasts (Levrero et al., 2000; Li et al., 2005) . In differentiated myotubes, CDDP induces, albeit less efficiently than doxorubicin, both caspase 7 cleavage and apoptosis (Figure 4c and d) . We found that abrogation of DNp73 expression using specific siRNAs results in a sharp increase of cisplatin-induced apoptosis of differentiated myocytes, that was inhibited in turn when TAp73 expression was abolished and only marginally affected by targeting p53 expression (Figure 4e ). These results indicate that p73 proteins also play an important role in determining the response Figure 3 (a) C2C12 cells were transiently transfected using Lipofectamine reagent (Invitrogen) with MLCbgal reporter gene (Sartorelli et al., 1999) either alone or in combination with the indicated plasmids. After 48 h in DM, b-galactoside activity in situ was assayed (Wu et al., 2000) . DNp73 in myogenic differentiation L Belloni et al of differentiated myocytes to DNA damage. TAp73 mediates apoptosis in myotubes exposed to DNA damage independently from the ability of the stimulus to activate p53 (Figure 4d ). DNp73 expression in differentiated myotubes clearly contributes to their relative resistance to DNA damage.
Conclusions
In this study, we provide a comprehensive evaluation of the expression profile and functional role of DN-and
TAp73 proteins in a model of skeletal muscle differentiation. DNp73a isoform accumulates in differentiating myocytes as a result of the coordinated action of MyoD and p73/p53 to upregulate the P2p73 promoter activity. We also show that ZEB inhibits the P2p73 promoter activity in differentiated C2C12 cells and counteracts its activation by MyoD, which competes with ZEB for binding to the same Ebox-like sequences to activate transcription (Fontemaggi et al., 2001) . DNp73 expression raises early during differentiation and protects myoblasts that fail to accomplish the differentiation program from undergoing spontaneous 
fold induction Figure 4 (a and b) Targeted degradation of DNp73 transcripts by specific siRNAs enhances differentiation-associated apoptosis of C2C12 cells. C2C12 myoblasts were transiently transfected with the indicated siRNA. At 24 h post-transfection, cell cultures were shifted to DM and after 24 h the cells were fixed by formaldelyde 4% and stained with Hoechst 33258 (SIGMA). Apoptosis was monitored by quantifying the percentage of Hoechst-stained nuclei undergoing chromatin condensation and nuclear fragmentation (a) and by immunoblotting using an antibody that recognizes the caspase-7-cleaved fragment (cell signaling) (b). Results in (a) are shown as means from three experiments 7s.d. (c) C2C12 myotubes (DM 72 h) were treated with either 25 mM cisplatin (CDDP) or 1 mM dororubicin (Doxo) for 24 h and apoptosis assessed as in (a). In (d), C2C12 myotubes were treated with either Doxo 0.5 to 1 mM or CDDP 2-25 mM for 24 h, and cell extracts were assayed by immunoblotting with anti-Ser15/18 and phopsho-p53 (cell signaling), and for caspase 7 cleavage (cell signaling). Densitometric analisis of caspase-7-cleaved fragment is shown in the lower panel. Data are expressed as fold increase (mean7s.d.) from three independent experiments, (e) Abrogation of DNp73 expression by specific siRNAs enhances apoptosis of C2C12 myotubes exposed to CDDP. C2C12 myoblasts were transiently transfected with the indicated siRNA, differentiated in DM for 48 h and then treated with CDDP (25 mM) for 24 h. Apoptosis was monitored as in (b). Densitometric analylsis of caspase-7-cleaved fragment has been performed as in (d).
DNp73 in myogenic differentiation L Belloni et al apoptosis (Wang and Walsh, 1996) . Interestingly, abrogation of p53 expression by RNA interference has no effect on myoblasts apoptosis whereas the inihibition of TAp73 expression lowers the rate of C2C12 cell death. Altogether, these results implicate TAp73 rather than p53 in the spontaneous apoptosis of skeletal satellite cells committed to differentiate. We also show that endogenous DNp73 protects differentiated myocytes from cisplatin-induced apoptosis. These results suggest that DNp73 expression contributes to the different behaviour of undifferentiated proliferating myoblasts (sensitive) and differentiated myotubes (partly resistant) in response to several DNA-damaging pro-apoptotic agents (Latella et al., 2004) . On the basis of these observations, DNp73a might represent an important target in designing strategies aimed at the potentiation of the regenerative potential of skeletal satellite cells.
